On the flip side of the buyout binge that we're seeing, biotech IPOs are turning in weak performances. No longer an exit strategy for investors, IPOs are increasingly likely to garner only enough money to take a drug developer through one more stage of the development process. In addition, investors are becoming increasingly picky about the kind of companies that they're willing to invest in. That can only help the trend toward mergers. The Boston Globe looks at the numbers and the market trend.
- see the article from the Boston Globe on IPOs
PLUS: Artes Medical, which has been developing permanent dermatological products, has filed for a $75 million IPO. Release